| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,§
*
Department of Microbiology and the Carter Immunology Center, University of Virginia, Charlottesville, VA 22908;
Department of Chemistry, University of Virginia, Charlottesville, VA 22901;
MRC Centre for Immune Regulation and Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom; and
§
Department of Pathology, University of Virginia, Charlottesville, VA 22904
Using synthetic peptides, the HLA-B27-restricted CTL response to EBV in asymptomatic virus carriers has been mapped to four epitope regions in EBV latent cycle Ags. One of these peptide-defined epitopes (RRIYDLIEL) tends to be immunodominant and is recognized in the context of all three B27 subtypes studied, B*2702, B*2704, and B*2705. The other peptide-defined epitopes induce responses only in the context of one subtype, the immunogenic combinations being RRARSLSAERY/B*2702, RRRWRRLTV/B*2704, and FRKAQIQGL/B*2705. We used immunoaffinity chromatography to isolate the naturally presented viral peptides associated with these MHC class I molecules on the surface of EBV-transformed B-LCL. Using CTL reconstitution assays in conjunction with mass spectrometry, we established that the naturally processed and presented peptides are identical with the previously identified synthetic sequences. Despite the subtype-specific immunogenicity of three of the four epitopes, all four epitope peptides were found in association with each of the three different HLA-B27 subtypes. Indeed, those peptides that failed to induce a response in the context of a particular HLA-B27 subtype were frequently presented at greater abundance by that subtype than were the immunogenic peptides. Furthermore, among the peptides that did induce a response, immunodominance did not correlate with epitope abundance; in fact the immunodominant RRIYDLIEL epitope was least abundant, being present at less than one copy per cell. The relationship of this unexpected finding to the persistence of EBV is discussed.
This article has been cited by other articles:
|
|
 |
|
  R. J. Stoffels and H. G. Spencer An Asymmetric Model of Heterozygote Advantage at Major Histocompatibility Complex Genes: Degenerate Pathogen Recognition and Intersection Advantage Genetics, March 1, 2008; 178(3): 1473 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Assarsson, J. Sidney, C. Oseroff, V. Pasquetto, H.-H. Bui, N. Frahm, C. Brander, B. Peters, H. Grey, and A. Sette A Quantitative Analysis of the Variables Affecting the Repertoire of T Cell Specificities Recognized after Vaccinia Virus Infection J. Immunol., June 15, 2007; 178(12): 7890 - 7901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Wiertz, R. Devlin, H. L. Collins, and M. E. Ressing Herpesvirus Interference with Major Histocompatibility Complex Class II-Restricted T-Cell Activation J. Virol., May 1, 2007; 81(9): 4389 - 4396. [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. York, M. A. Brehm, S. Zendzian, C. F. Towne, and K. L. Rock Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance PNAS, June 13, 2006; 103(24): 9202 - 9207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. E. Tynan, D. Elhassen, A. W. Purcell, J. M. Burrows, N. A. Borg, J. J. Miles, N. A. Williamson, K. J. Green, J. Tellam, L. Kjer-Nielsen, et al. The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation J. Exp. Med., November 7, 2005; 202(9): 1249 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kotsiopriftis, J. E. Tanner, and C. Alfieri Heat Shock Protein 90 Expression in Epstein-Barr Virus-Infected B Cells Promotes {gamma}{delta} T-Cell Proliferation In Vitro J. Virol., June 1, 2005; 79(11): 7255 - 7261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Long, T. A. Haigh, N. H. Gudgeon, A. M. Leen, C.-W. Tsang, J. Brooks, E. Landais, E. Houssaint, S. P. Lee, A. B. Rickinson, et al. CD4+ T-Cell Responses to Epstein-Barr Virus (EBV) Latent-Cycle Antigens and the Recognition of EBV-Transformed Lymphoblastoid Cell Lines J. Virol., April 15, 2005; 79(8): 4896 - 4907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yoshimura, R. Yadav, G. J. Christianson, W. U. Ajayi, D. C. Roopenian, and S. Joyce Duration of Alloantigen Presentation and Avidity of T Cell Antigen Recognition Correlate with Immunodominance of CTL Response to Minor Histocompatibility Antigens J. Immunol., June 1, 2004; 172(11): 6666 - 6674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Purcell and J. J. Gorman Immunoproteomics: Mass Spectrometry-based Methods to Study the Targets of the Immune Response Mol. Cell. Proteomics, March 1, 2004; 3(3): 193 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Novitsky, H. Cao, N. Rybak, P. Gilbert, M. F. McLane, S. Gaolekwe, T. Peter, I. Thior, T. Ndung'u, R. Marlink, et al. Magnitude and Frequency of Cytotoxic T-Lymphocyte Responses: Identification of Immunodominant Regions of Human Immunodeficiency Virus Type 1 Subtype C J. Virol., September 11, 2002; 76(20): 10155 - 10168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. DiPaolo and E. R. Unanue Cutting Edge: Chemical Dominance Does Not Relate to Immunodominance: Studies of the CD4+ T Cell Response to a Model Antigen J. Immunol., July 1, 2002; 169(1): 1 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Rodriguez, S. Harkins, M. K. Slifka, and J. L. Whitton Immunodominance in Virus-Induced CD8+ T-Cell Responses Is Dramatically Modified by DNA Immunization and Is Regulated by Gamma Interferon J. Virol., March 27, 2002; 76(9): 4251 - 4259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. M. Boon, G. de Mutsert, Y. M. F. Graus, R. A. M. Fouchier, K. Sintnicolaas, A. D. M. E. Osterhaus, and G. F. Rimmelzwaan The Magnitude and Specificity of Influenza A Virus-Specific Cytotoxic T-Lymphocyte Responses in Humans Is Related to HLA-A and -B Phenotype J. Virol., January 15, 2002; 76(2): 582 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Smith, P. M. Patel, J. Porte, P. J. Selby, and A. M. Jackson Human Dendritic Cells Genetically Engineered to Express a Melanoma Polyepitope DNA Vaccine Induce Multiple Cytotoxic T-Cell Responses Clin. Cancer Res., December 1, 2001; 7(12): 4253 - 4261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Herberts, K. J. Stittelaar, E. van der Heeft, J. van Gaans-van den Brink, M. C. M. Poelen, P. J. M. Roholl, L. J. W. van Alphen, C. J. M. Melief, A. P. J. M. de Jong, and C. A. C. M. van Els A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway J. Gen. Virol., September 1, 2001; 82(9): 2131 - 2142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Skoberne, R. Holtappels, H. Hof, and G. Geginat Dynamic Antigen Presentation Patterns of Listeria monocytogenes-Derived CD8 T Cell Epitopes In Vivo J. Immunol., August 15, 2001; 167(4): 2209 - 2218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Subklewe, C. Paludan, M. L. Tsang, K. Mahnke, R. M. Steinman, and C. Munz Dendritic Cells Cross-present Latency Gene Products from Epstein-Barr Virus-transformed B Cells and Expand Tumor-reactive CD8+ Killer T Cells J. Exp. Med., February 5, 2001; 193(3): 405 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Anderton, C. G. Radu, P. A. Lowrey, E. S. Ward, and D. C. Wraith Negative Selection during the Peripheral Immune Response to Antigen J. Exp. Med., December 27, 2000; 193(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Blake, T. Haigh, G. Shaka'a, D. Croom-Carter, and A. Rickinson The Importance of Exogenous Antigen in Priming the Human CD8+ T Cell Response: Lessons from the EBV Nuclear Antigen EBNA1 J. Immunol., December 15, 2000; 165(12): 7078 - 7087. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
